Holen Sie sich die Stockscreener-App
0.9001
4.69%
0.0403
Handel nachbörslich:
.92
0.0199
+2.21%
Schlusskurs vom Vortag:
$0.8598
Offen:
$0.87
24-Stunden-Volumen:
644.76K
Relative Volume:
0.98
Marktkapitalisierung:
$100.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.91M
KGV:
-4.0914
EPS:
-0.22
Netto-Cashflow:
$-19.57M
1W Leistung:
+15.83%
1M Leistung:
+8.29%
6M Leistung:
-26.22%
1J Leistung:
-29.13%
1-Tages-Spanne:
$0.8494
$0.9147
1-Wochen-Bereich:
$0.78
$0.9147
52-Wochen-Spanne:
$0.5526
$1.66
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Firmenname
Atossa Therapeutics Inc
Sektor
Branche
Telefon
206.588.0256
Adresse
10202 5TH AVENUE NE, SEATTLE, WA
Vergleichen Sie ATOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.9001 | 100.38M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-01-26 | Eingeleitet | Maxim Group | Buy |
Atossa Therapeutics Inc Aktie (ATOS) Neueste Nachrichten
Ascendiant Capital Markets Issues Positive Forecast for Atossa Therapeutics (NASDAQ:ATOS) Stock Price - Defense World
Craig Hallum Upgrades Atossa Therapeutics (NASDAQ:ATOS) to “Strong-Buy” - Defense World
Atossa Therapeutics (ATOS): Ascendiant Capital Raises Price Target | ATOS Stock News - GuruFocus
Ascendiant Capital raises Atossa Genetics stock price target to $7.50 - Investing.com
Craig-Hallum Initiates Coverage of Atossa Therapeutics (BMV:ATOS) with Buy Recommendation - Nasdaq
Craig-Hallum Initiates Coverage of Atossa Therapeutics (ATOS) with Buy Recommendation - Nasdaq
This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Craig-Hallum Initiates Coverage on Atossa Therapeutics (ATOS) with Buy Rating | ATOS Stock News - GuruFocus
Atossa Therapeutics at Jefferies Conference: Strategic Moves in Breast Cancer - Investing.com Canada
Atossa Therapeutics (ATOS) Receives Buy Rating with Promising Ca - GuruFocus
Craig Hallum Initiates Coverage on Atossa Therapeutics With Buy Rating, $4 Price Target - marketscreener.com
Atossa Therapeutics (ATOS) Receives Positive Coverage and Price Target | ATOS Stock News - GuruFocus
Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference - Bluefield Daily Telegraph
Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference | ATOS Stock News - GuruFocus
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Northern Trust Corp - Defense World
Atossa Therapeutics Reports Q1 2025 Financial Results - TipRanks
Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock - Investing.com Australia
Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock By Investing.com - Investing.com Nigeria
Transcript : Atossa Therapeutics, Inc.Special Call - marketscreener.com
Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 - ACCESS Newswire
Atossa Therapeutics announces issuance of U.S. patent - MSN
Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 | ATOS Stock News - GuruFocus
Atossa CEO to Reveal Latest Phase 2 Results for Next-Gen Breast Cancer Drug in Exclusive Investor Webinar - Stock Titan
HC Wainwright Issues Optimistic Outlook for ATOS Earnings - Defense World
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? - Yahoo Finance
Atossa Therapeutics (ATOS) Reports Promising Phase 2 Trial Resul - GuruFocus
Atossa Therapeutics Announces Full Results from I?SPY?2 Endocrin - GuruFocus
Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen - StreetInsider
Wells Fargo & Company MN Has $68,000 Stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics Announces First Quarter 2025 Financial Resul - GuruFocus
Atossa Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update - goSkagit
ATOSSA THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update | ATOS Stock News - GuruFocus
Barclays PLC Has $181,000 Holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics (ATOS) to Release Quarterly Earnings on Monday - Defense World
Atossa Therapeutics reports progress in breast cancer treatments - MSN
Atossa Therapeutics and Ainos Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - standard-journal.com
JPMorgan Chase & Co. Buys 211,654 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
ATOS: Atossa Therapeutics Secures New Patent for (Z)-endoxifen F - GuruFocus
ATOS: Atossa Therapeutics Secures New Patent for (Z)-endoxifen Formulations | ATOS Stock News - GuruFocus
A look into Atossa Therapeutics Inc (ATOS)’s deeper side - Sete News
LPL Financial LLC Cuts Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics Inc (ATOS)’s results reveal risk - uspostnews.com
Atossa Therapeutics Inc (ATOS) rating initates by Maxim Group - knoxdaily.com
Sector Update: Health Care - marketscreener.com
Atossa Therapeutics (ATOS) Secures Patent for Key Breast Cancer Drug Formulations - GuruFocus
Atossa stock gains on U.S. patent win (ATOS:NASDAQ) - Seeking Alpha
Atossa Therapeutics Inc (ATOS) Stock: Navigating a Year of Volatility - investchronicle.com
Atossa Therapeutics Gets US Patent Covering (Z)-endoxifen Breast Cancer Treatment - marketscreener.com
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281 - GuruFocus
Finanzdaten der Atossa Therapeutics Inc-Aktie (ATOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):